KD Logo

Director Krognes Steve E. sale 30,000 shares of Denali Therapeutics Inc [DNLI]

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Denali Therapeutics Inc shares valued at $870,900 were sold by Krognes Steve E. on Sep 30 ’24. At $29.03 per share, Krognes Steve E. sold 30,000 shares. The insider’s holdings dropped to 29,096 shares worth approximately $0.8 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Also, STEVE KROGNES purchased 30,000 shares, netting a total of over 882,900 in proceeds.

Before that, SATO VICKI L had sold 1,020 shares from its account. In a trade valued at $30,600, the Director traded Denali Therapeutics Inc shares for $30.00 each. Upon closing the transaction, the insider’s holdings decreased to 1,020 shares, worth approximately $3.16 million.

Analysts at Cantor Fitzgerald downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in early October. As of December 13, 2023, Citigroup has initiated its “Buy” rating for DNLI.

Analyzing DNLI Stock Performance

During the last five days, there has been a surge of approximately 6.53%. Over the course of the year, Denali Therapeutics Inc shares have jumped approximately 27.77%. Shares of the company reached a 52-week high of $32.13 on 09/18/24 and a 52-week low of $14.56 on 04/25/24. A 50-day SMA is recorded $26.62, while a 200-day SMA reached $21.39. Nevertheless, trading volume fell to 0.54 million shares from 0.65 million shares the previous day.

Support And Resistance Levels for Denali Therapeutics Inc (DNLI)

According to the 24-hour chart, there is a support level at 27.10, which, if violated, would cause prices to drop to 26.77. In the upper region, resistance lies at 27.83. The next price resistance is at 28.23. RSI (Relative Strength Index) is 49.32 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.26, which suggests the price will decrease in the coming days. Percent R is at 51.25%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Most Popular